Acquisition Agriculture Biotech China Covid-19 Currency European Expansion Finance Investment Pacific Pharmaceutical Revenue Russia Sanctions stock market stocks
JuSun/iStock via Getty Images Illumina (NASDAQ:ILMN) operates in the genetic and genomic analysis sector, supplying a range of products and services to both research and clinical environments. The firm’s offerings aim to streamline the integration of genomic technologies across numerous applications. The customer base of Illumina is wide-ranging, encompassing genomic research centers, academic institutions, governmental laboratories, hospitals, and entities within the pharmaceutical, biotechnology, and consumer genomics industries. Illumina’s product suite includes sequencing and microarray systems, consumables, and analysis tools. This portfolio is tailored to meet the diverse requirements associated with genomic complexity, varying price sensitivities, and throughput demands. I previously…
News Timeline:
Track the development of this news story across the Internet.